DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Health Insurance Innovations Sees FY20 Adj. EPS $3.10-$4.15 vs $4.72 Est., Sales $290M-$350M

The Company’s guidance for the full year ending December 31, 2020 is based on information available as of March 3, 2020. These expectations are forward-looking statements, and the Company assumes no obligation to

Benzinga · 03/03/2020 21:03

The Company’s guidance for the full year ending December 31, 2020 is based on information available as of March 3, 2020. These expectations are forward-looking statements, and the Company assumes no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this release and in the Company’s annual and quarterly filings with the Securities and Exchange Commission.

The following is guidance for the full year ending December 31, 2020.

  • Total revenue is expected to be in the range of $290 million to $350 million. Revenue from the Medicare segment is expected to be in the range of $190 million to $210 million. Revenue from the IFP segment is expected to be in the range of $100 million to $140 million.
  • Adjusted net income per share is expected to be in the range of $3.10 to $4.15.
  • Adjusted EBITDA is expected to be in the range of $65.0 million to $80.0 million.
  • Profit from the Medicare (3) segment is expected to be in the range of $70.0 million to $80.0 million. Profit from the IFP segment is expected to be in the range of $15.0 million to $20.0 million.
  • Corporate (4) expense is expected to be approximately $20.0 million.
  • The company expects cashflow to be approximately breakeven in 2020.